Wells Fargo & Company MN Decreases Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Wells Fargo & Company MN trimmed its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 17.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 96,952 shares of the specialty pharmaceutical company's stock after selling 20,063 shares during the quarter. Wells Fargo & Company MN owned about 0.16% of Jazz Pharmaceuticals worth $11,940,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of JAZZ. Pacer Advisors Inc. raised its holdings in shares of Jazz Pharmaceuticals by 5.5% during the fourth quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company's stock valued at $272,713,000 after purchasing an additional 115,102 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Jazz Pharmaceuticals by 4.8% during the 4th quarter. JPMorgan Chase & Co. now owns 1,587,541 shares of the specialty pharmaceutical company's stock valued at $195,506,000 after buying an additional 72,007 shares during the last quarter. Franklin Resources Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 4.6% during the 3rd quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company's stock valued at $124,208,000 after buying an additional 48,708 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 15.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 615,517 shares of the specialty pharmaceutical company's stock valued at $75,801,000 after buying an additional 83,807 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in shares of Jazz Pharmaceuticals by 5.4% in the 4th quarter. Bank of New York Mellon Corp now owns 477,751 shares of the specialty pharmaceutical company's stock worth $58,835,000 after buying an additional 24,481 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Trading Up 1.2 %

Shares of NASDAQ:JAZZ traded up $1.23 during trading on Friday, reaching $102.78. 995,175 shares of the company were exchanged, compared to its average volume of 789,501. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The firm has a market capitalization of $6.24 billion, a PE ratio of 14.48, a P/E/G ratio of 1.04 and a beta of 0.42. The business's fifty day simple moving average is $127.60 and its 200-day simple moving average is $122.50. Jazz Pharmaceuticals plc has a 12-month low of $95.49 and a 12-month high of $148.06.

Wall Street Analyst Weigh In

JAZZ has been the subject of several analyst reports. Truist Financial upped their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. Barclays reiterated an "overweight" rating and issued a $200.00 target price (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. UBS Group raised Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $145.00 to $179.00 in a research note on Friday, March 7th. Cantor Fitzgerald lowered shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and raised their target price for the company from $140.00 to $150.00 in a report on Wednesday, February 26th. Finally, Wells Fargo & Company upgraded shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and increased their price objective for the company from $130.00 to $170.00 in a research report on Thursday, February 13th. One research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of "Buy" and a consensus target price of $187.71.

Insider Buying and Selling

In other news, CAO Patricia Carr sold 4,813 shares of the stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $144.42, for a total transaction of $695,093.46. Following the transaction, the chief accounting officer now owns 8,237 shares of the company's stock, valued at approximately $1,189,587.54. This represents a 36.88 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $122.31, for a total transaction of $183,465.00. Following the transaction, the chief executive officer now owns 439,744 shares in the company, valued at approximately $53,785,088.64. The trade was a 0.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 28,736 shares of company stock valued at $4,023,305 over the last quarter. 4.20% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.